Cell penetrating elastin-like polypeptides for therapeutic peptide delivery

Area of Science:

• Biotechnology
• Oncology
• Drug Delivery

Background:

• Current solid tumor treatments face limitations due to non-specific drug delivery and significant systemic toxicity.
• Peptide therapeutics offer targeted cancer treatment potential but suffer from poor pharmacokinetics and cellular permeability.
• Developing targeted delivery systems is crucial to overcome these limitations and enhance therapeutic efficacy.

Purpose of the Study:

• To review the development of elastin-like polypeptides (ELPs) as carriers for thermally targeted delivery of therapeutic peptides (TPs).
• To explore the use of cell-penetrating peptides (CPPs) to enhance intracellular delivery of ELP-fused TPs.
• To assess the potential of CPP-fused ELPs in preclinical cancer models.

Main Methods:

• Development and characterization of elastin-like polypeptide (ELP) constructs.
• Fusion of therapeutic peptides (TPs) with ELPs and cell-penetrating peptides (CPPs).
• In vitro and in vivo evaluation of ELP-based drug delivery systems in various cancer models.

Main Results:

• CPP-fused ELPs successfully delivered peptide inhibitors of c-Myc and p21 in vitro.
• These novel constructs demonstrated promising results in preclinical models of breast and brain cancer.
• The thermally targeted delivery approach using ELPs shows potential for localized cancer treatment.

Conclusions:

• Elastin-like polypeptides (ELPs) fused with cell-penetrating peptides (CPPs) represent a promising strategy for targeted cancer therapy.
• This approach enhances intracellular delivery of therapeutic peptides, potentially reducing systemic toxicity.
• Further development of ELP-CPP conjugates holds significant potential for treating localized solid tumors.